参考文献/References:
[1] Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics,2015. CA Cancer J Clin. 2015 Jan - Feb; 65 ( 1) : 5-29.
[2] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin - paclitaxel in pulmonary adenocarcinoma[ J] . N Engl J Med. 2009,361( 10) :947 -957.
[3] Maemondo M, Inoue A, Kobayashi K, et al. Geftinib or chemotherapy for non - small - cell lung cancer with mutated EGFR[ J] . N Engl J Med. 2010, 362( 25) : 2380-2388.
[4] Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/ carboplatin for advanced non - small cell lung cancer[ J] . J Thorac Oncol. 2010, 5( 9) :1416 -1423.
[5] Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin -gemcitabine and bevacizumab or placebo as first - line therapy for nonsquamous non -small - cell lung cancer: results from a randomised phase III trial ( AVAiL) . Ann Oncol. 2010 Sep; 21 ( 9) : 1804-1809.
[6] Z. N. van, Neoadjuvant strategies for non - small cell lung cancer[ J] . Lung Cancer. 2001,34:145 -150.
[7] J. T. Schiffer, L Corey. Rapid host immune response and viral dynamics in herpes simplex virus - 2 infection[ J] Nat Med. 2013,19:280 -290.
[8]李杰,郭秋均,林洪生.中医药对肿瘤免疫抑制微环境的调控作用及分子机制研究[C].//第五届国际中医?中西医结合肿瘤学术交流大会暨第十四届全国中西医结合肿瘤学术大会论文集.2014:14.
[9]陈光伟,殷群,吕予.恶性肿瘤转移中医防治浅析[J].陕西中医,2011,32(5):638-639.
[10]王书航,王洁.2018年V3版非小细胞肺癌指南更新要点解读[J].华西医学,2018,33(4):388-392.
[11]汤钊猷.现代肿瘤学[M].上海,复旦大学出版社,2014:1070-1122.
[12]杨学宁,吴一龙.实体瘤治疗疗效评价标准—RECIST[J].循证医学,2004,4(2):85-90.
[13]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:211.
[14]章永红,叶丽红,彭海燕等.论“全力扶正?尽力攻毒”的抗癌基本原则[J].中华中医药杂志,2015,30(12):4230-4232.
[15]江锋,叶永安.关于中医肿瘤临床疗效评价的思考[J].中华中医药学刊,2008,26(3):525-527.
[16]林洪生,张英.中医治疗肿瘤评价方法现状与体会[J].世界科学技术(中医药现代化),2009,11(5):739-741.
[17]朱渊红,吕昕,徐婷贞.利肺健脾方联合化疗治疗晚期非小细胞肺癌临床疗效观察[J].中华中医药杂志,2017,32(1):360-362.
[18]杨洋,杨得振.中西医结合治疗中晚期非小细胞肺癌[J].现代中西医结合杂志,2011,20(12):1445-1446+1491.
[29] Souptik Barua, Penny Fang, Amrish Sharma, et al. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non - small cell lung cancer[ J] . Lung Cancer. 2018,3( 117) :73 -79.
[20] Si - Pei Wu, Ri - Qiang Liao, Hai - Yan Tu, et al. Stromal PD - L1 - Positive Regulatory T cells and PD -1 - Positive CD8 - Positive T cells Define the Response of Different Subsets of Non - Small Cell Lung to PD -1/ PD - L1 Blockade Immunotherapy [ J] . Journal of Thoracic Oncology.2018,4( 13) :521 -532.
相似文献/References:
[1]关茜１ 焦俊?１ 叶子豪１ 王克穷２.益脾扶正方联合化疗治疗中晚期食管癌 ２１ 例[J].陕西中医药大学学报,2019,(01):150.[doi:10.13424/j.cnki.jsctcm.2019.01.045]
Guan Qian Jiao Junzhe Ye Zihao Wang Keqiong.Clinical Analysis of Yipi Fuzheng Recipe combined with Chemotherapy in the Treatment of Advanced Esophageal Cancer[J].Journal of Shaanxi University of Traditional Chinese Medicine,2019,(5):150.[doi:10.13424/j.cnki.jsctcm.2019.01.045]
[2]尹湘君 阮家钊 柴毅 季旭明.非小细胞肺癌化疗后温下方加减干预临床疗效研究[J].陕西中医药大学学报,2021,44(02):075.[doi:10.13424/j.cnki.jsctcm.2021.02.015]
YIN Xiang - jun,RUAN Jia - zhao,CHAI Yi,et al.Study on The Clinical Effects of Modified Warming Purging Prescription intervention after Chemotherapy for Non – small Cell Lung Cancer[J].Journal of Shaanxi University of Traditional Chinese Medicine,2021,44(5):075.[doi:10.13424/j.cnki.jsctcm.2021.02.015]
[3]党明 翟鑫.胃癌术后化疗联合益气逐瘀汤治疗有效性研究[J].陕西中医药大学学报,2022,(06):128.[doi:10.13424/j.cnki.jsctcm.2022.06.025]
[4]陈晨马海龙成玲玲岳伟马霜顾银霞徐建林.柴胡桂枝干姜汤加味联合化疗治疗胆热脾寒型晚期胰腺癌临床研究[J].陕西中医药大学学报,2024,(01):076.[doi:10.13424/j.cnki.jsctcm.2024.01.015]